Benzinga·Jun 30, 2026
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market OpportunityGenmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
Genmab A/S(GMAB)Earnings, Financials & Key Ratios
GMAB•NASDAQ
$29.18
18.9× P/E·Price updated Jul 7, 2026
AboutGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Show more
- Revenue$3.72B-82.7%
- EBITDA$1.32B-81.4%
- Net Income$964M-87.7%
- EPS (Diluted)1.54-87.3%
- Gross Margin91.69%-3.9%
- EBITDA Margin35.51%+7.4%
- Operating Margin33.6%+7.9%
- Net Margin25.89%-29.0%
- ROE4.53%-80.3%
GMAB Price & Volume
Genmab A/S (GMAB) stock price & volume — 10-year historical chart
Loading chart...
Royalty Revenue Volatility Masks Strategic Pipeline Expansion
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strong
Financial:Mixed
Cash Flow:Mixed
Primary Risk:Regulatory pricing pressure risk
Key Thesis Takeaways
- Genmab's long-term value proposition remains anchored in its high-margin antibody engineering platform, though the transition from a cash-rich royalty collector to an acquisitive industrial player introduces significant execution risk.
- While the company maintains a robust gross margin profile consistently exceeding 91%, investors must weigh the potential impact of IRA-driven pricing pressure on its core Darzalex royalty stream against the long-term growth potential of its recent $7.2B acquisition.
- The shift toward a more leveraged capital structure, evidenced by a debt-to-equity ratio rising to 0.94, suggests a fundamental change in risk profile that warrants careful monitoring of future milestone-driven cash flows.
Verdict Logic
while the company maintains a robust 92.7% gross margin, the significant compression of the current ratio to 2.18 and increased debt reliance suggest investors should wait for more consistent cash flow generation before increasing exposure.
GMAB Growth Metrics
Genmab A/S (GMAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.63%
5 Years-18.11%
3 Years-36.45%
TTM-34.41%
Profit CAGR
10 Years2.36%
5 Years-27.34%
3 Years-43.88%
TTM-52.54%
EPS CAGR
10 Years2.03%
5 Years-26.58%
3 Years-42.87%
TTM-59.7%
Return on Capital
10 Years20.83%
5 Years15.74%
3 Years13.51%
Last Year4.82%
GMAB Recent Earnings
Genmab A/S (GMAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.15+0.0%
$0.15
Rev
$896M-1.1%
$906M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.05-89.1%
$0.46
Rev
$1.1B-0.8%
$1.1B
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.65+35.4%
$0.48
Rev
$1.0B+1.1%
$1.0B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.54+38.5%
$0.39
Rev
$925M-2.9%
$953M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.15vs $0.15+0.0% | $896Mvs $906M-1.1% |
| Q1 2026 | Feb 17, 2026 | $0.05vs $0.46-89.1% | $1.1Bvs $1.1B-0.8% |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.48+35.4% | $1.0Bvs $1.0B+1.1% |
| Q3 2025 | Aug 7, 2025 | $0.54vs $0.39+38.5% | $925Mvs $953M-2.9% |
Based on last 12 quarters of dataView full earnings history →
Latest GMAB News
Recent stock market news and headlines for Genmab A/S (GMAB)
WSJ·Jun 30, 2026
Genmab Shares Climb After Lymphoma Therapy Hits Goal in TrialThe Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
GlobeNewsWire·Jun 29, 2026
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free SurvivalCompany Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCL COPENHAGEN, Denmark; June 29, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of treatment. Based on topline results, the trial met its primary objective, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS).
GlobeNewsWire·Jun 16, 2026
Capital Increase in Genmab as a Result of Employee Warrant ExerciseCompany Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
GlobeNewsWire·Jun 15, 2026
Major Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12, 2026, Orbis Investment Management Limited controlled the voting rights to 3,112,476 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.
Peers Comparison
Key metrics vs top competitors for Genmab A/S (GMAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.18 | $17.91B | 18.95 | -82.7% | 25.89% | 4.53% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $118.05 | $23.58B | 18.42 | 21.22% | 26.71% | 29.31% | — | |
| $57.08 | $14.5B | 20.53 | 6.98% | 35.08% | 40.21% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — |
Compare GMAB vs Peers
Genmab A/S (GMAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GMAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GMAB Frequently Asked Questions
Genmab A/S (GMAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Genmab A/S's revenue?
Genmab A/S (GMAB) reported $8.84B in revenue for fiscal year 2025.
How fast is Genmab A/S growing?
Genmab A/S (GMAB) saw revenue decline by 82.7% over the past year.
Is GMAB profitable?
Yes, Genmab A/S (GMAB) is profitable, generating $2.61B in net income for fiscal year 2025 (25.9% net margin).
Dividend & Returns
What is GMAB's return on equity?
Genmab A/S (GMAB) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
What is Genmab A/S's free cash flow?
Genmab A/S (GMAB) generated $1.15B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.